Frequently Asked Questions

→ All partner clinics have cell processing facilities (specific cell processing facilities) officially registered and maintained with the Ministry of Health, Labor and Welfare .

Safety and quality are guaranteed because they are cultured directly in a sterile facility within the hospital .

Cultured NK cells are activated on average by 65% (range: 45-85%) compared to conventional cells. At least 3-5 billion cells are cultured. While this varies by patient, patients with extremely low NK cell counts may only receive around 1 billion cells.

Additionally, a culture result report is provided for each session so that patients can check it directly.

→ Rarely, temporary fever, chills, and fatigue may occur, but most recover within 1 to 2 days.

→ Yes, it is possible.

NK immunotherapy can be used in conjunction with the latest immunotherapy drugs, such as Opdivo (Nivolumab) and Yervoy (Ipilimumab), to further enhance the therapeutic effect.

→ Yes. In addition to NK cells , iNKT cell therapy and activated lymphocyte therapy (CD3-LAK) can be performed according to the patient's condition.

→ Yes. **Opdivo (Nivolumab)** and **Yervoy (Ipilimumab)** are cutting-edge anticancer drugs that work by disarming cancer cells' "defense shields," and are used in conjunction with NK cell therapy when necessary. Opdivo is usually used first, and if the response is insufficient, Yervoy is added or switched.

→ There are individual differences, but the effects usually last for several months to more than a year .

In particular, iNKT treatment can induce long-term immune memory, which can have a long-lasting effect in preventing relapse.

NK immunotherapy typically requires 3 to 6 treatment cycles. A personalized treatment plan is developed based on your disease stage, immune status, and any concurrent cancer therapies.

iNKT treatment is given in two sets, approximately one month after the first session.

A second dose is administered.

The third dose is given between six months and one year thereafter.